The heart drug continues to test well in clinical trials.
News & Analysis: Amarin
The stocks of Amarin and Clean Energy Fuels are down 90% off their highs -- but both could bounce back in a big way.
Just one day after hearing arguments, the U.S. Court of Appeals delivered a ruling that Amarin shareholders did not want to hear.
An appeal hearing for Vascepa's patent case isn't sitting well with investors.
The company's second-quarter earnings report was less than encouraging.
AMRN earnings call for the period ending June 30, 2020.
The big wild card for the company now is its appeal of a court ruling invalidating key patents for the high triglyceride drug.
The pharma stock collapsed on the threat of generic competition for a drug that launched in December 2019, but the move may have been a bit of an overreaction.
The arrival of a generic version of Vascepa will be bad news for the company.
U.S. patents protecting the only revenue source for this biotech company were recently invalidated, and the dust won't settle anytime soon.